The management of erectile dysfunction with placebo only: does it work?

Area of Science:

• Urology
• Clinical Pharmacology
• Psychosomatic Medicine

Background:

• Randomized clinical trials (RCTs) are crucial for medical evidence but are influenced by placebo effects, particularly in erectile dysfunction (ED) treatment.
• The placebo effect can reach up to 50% in RCTs for oral phosphodiesterase type-5 inhibitors (iPDE5) used as first-line ED therapy.

Purpose of the Study:

• To investigate the impact of therapeutic illusion on the efficacy of oral treatments for ED.
• To determine if patient expectations influence treatment outcomes in ED.

Main Methods:

• A prospective, single-blind, parallel-group study involving 123 ED patients randomly assigned to three groups.
• Group 1 received active treatment information, Group 2 received ambiguous information (active or placebo), and Group 3 was informed they received placebo.
• All patients received starch capsules, with outcomes assessed after 8 weeks using the International Index of Erectile Function (IIEF) and Quality of Erection Questionnaire.

Main Results:

• ED severity improved across all groups (31.7% to 36.8%), with no statistically significant differences between them (P=0.857).
• Improvements in the Quality of Erection Questionnaire were significant in the groups receiving ambiguous or placebo information (G2, G3).

Conclusions:

• Written-informed therapeutic illusion did not significantly alter ED treatment outcomes.
• Oral placebo administration demonstrated clinical effectiveness, improving erectile function and erection quality in ED patients.